DeepGLSTM: Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity
- Abstract
- Model Architecture
- Preparation
- Quick Start
- Pretrained Models and Dataset
- Model Performance Stats
- Case studies on SARS-CoV-2 viral proteins
- Citation
Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. Our proposed model has been trained on Davis, KIBA (Kinase Inhibitor Bioactivity), DTC (Drug Target Commons), Metz, ToxCast and STITCH datasets. We use our novel architecture to predict a Combined Score (calculated using Davis and KIBA score) of 2,304 FDA-approved drugs against 5 viral proteins. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2. Subsequently, this list may be used for the creation of new useful drugs. For more details please visit our work.
The dependency pakages can be installed using the command.
pip install -r requirements.txtIn our experiment we use Davis, Kiba, DTC, Metz, ToxCast, Stitch datasets respectively.
Dataset Statistics:
Firstly, run the script below to create Pytorch_Geometric file. The file will be created in processed folder in data folder.
python3 data_creation.py Default values of argument parser are set for davis dataset.
Run the following script to train the model.
python3 training.py Default values of argument parser are set for davis dataset.
Run the following script to test the model.
python3 inference.py Default values of argument parser are set for davis dataset.
| Dataset | Model download link |
|---|---|
| Davis | Link |
| Kiba | Link |
| DTC | Link |
| Metz | Link |
| ToxCast | Link |
| Stitch | Link |
Download models from the above table for particular dataset and store in the pretrained_model folder.
| Dataset | Dataset download links |
|---|---|
| Davis | Link |
| Kiba | Link |
| DTC | Link |
| Metz | Link |
| ToxCast | Link |
| Stitch | Link |
Download dataset from the above table for particular data and store in the data folder. For each folder in the link there are two csv file train and test.
Plots showing DeepGLSTM versus measured binding affinity values for the (a) Davis dataset (b) KIBA dataset (c) DTC dataset (d) Metz dataset (e) ToxCast dataset (f) STITCH dataset. In figure Coef_V is Pearson correlation coefficient.
Please cite our paper if it's helpful to you in your research.
@inbook{doi:10.1137/1.9781611977172.82,
author = {Shrimon Mukherjee and Madhusudan Ghosh and Partha Basuchowdhuri},
title = {DeepGLSTM: Deep Graph Convolutional Network and LSTM based approach for predicting drug-target binding affinity},
booktitle = {Proceedings of the 2022 SIAM International Conference on Data Mining (SDM)},
chapter = {},
pages = {729-737},
doi = {10.1137/1.9781611977172.82},
URL = {https://epubs.siam.org/doi/abs/10.1137/1.9781611977172.82},
eprint = {https://epubs.siam.org/doi/pdf/10.1137/1.9781611977172.82},
abstract = { Abstract Development of new drugs is an expensive and time-consuming process. Due to the world-wide SARS-CoV-2 outbreak, it is essential that new drugs for SARS-CoV-2 are developed as soon as possible. Drug repurposing techniques can reduce the time span needed to develop new drugs by probing the list of existing FDA-approved drugs and their properties to reuse them for combating the new disease. We propose a novel architecture DeepGLSTM, which is a Graph Convolutional network and LSTM based method that predicts binding affinity values between the FDA-approved drugs and the viral proteins of SARS-CoV-2. Our proposed model has been trained on Davis, KIBA (Kinase Inhibitor Bioactivity), DTC (Drug Target Commons), Metz, ToxCast and STITCH datasets. We use our novel architecture to predict a Combined Score (calculated using Davis and KIBA score) of 2,304 FDA-approved drugs against 5 viral proteins. On the basis of the Combined Score, we prepare a list of the top-18 drugs with the highest binding affinity for 5 viral proteins present in SARS-CoV-2. Subsequently, this list may be used for the creation of new useful drugs. }
}